RESEARCH TRIANGLE PARK, NC--(Marketwire - August 28, 2007) - A report by Cutting Edge
Information, "Pharmacoeconomics and Health Outcomes: Driving Formulary
Access and Reimbursement"
(
http://www.pharmacoeconomicsandhealthoutcomes.com), indicates that the
most accomplished pharmacoeconomics/health outcomes groups have realized
that early integration into product development gives them a competitive
edge.
Though the majority of the companies in this survey involve their health
outcomes teams by at least the end of Phase II, a number of companies
discussed conducting preparatory work as early as Phase I, or even
pre-clinical. The report finds that teams which finalize their
preparations while drug candidates are in Phase I or Phase II of testing,
place themselves in a better strategic position. By integrating themselves
earlier, these teams work with clinical development groups to ensure that
Phase III trials reach endpoints that deliver necessary pharmacoeconomics
and outcomes data.
Also, if health outcomes groups begin earlier they are able to fully
involve themselves in early clinical work, deepening their understanding of
disease areas and drug classes. This helps the groups better identify the
data and messaging that will support a brand's value proposition.
"By involving pharmacoeconomics teams early in drugs' lives, brand managers
gain the ability to build endpoints into trials that will enhance products'
value as they reach market," said David Richardson, a senior research
analyst at Cutting Edge Information. "For example, if a brand team
anticipates that a product needs a quality of life measure, the
pharmacoeconomics team will prepare a validated questionnaire to use in
Phase III trials. The team could not have offered this option if they were
not involved with the product until late in its life."
"Pharmacoeconomics and Health Outcomes: Driving Formulary Access and
Reimbursement," available at
http://www.pharmacoeconomicsandhealthoutcomes.com, examines eight major
pharmaceutical companies' pharmacoeconomics departments' strategies,
spending, structures and staffing. Compiled from interviews and surveys
with pharmacoeconomics directors, associate directors and executives, group
vice presidents and vice presidents of managed markets groups, the report
allows drug companies to compare and improve their own pharmacoeconomics
strategies.
"Pharmacoeconomics and Health Outcomes: Driving Formulary Access and
Reimbursement," available at
http://www.pharmacoeconomicsandhealthoutcomes.com, features key graphics
and metrics highlights including:
-- Pharmacoeconomics Budgets
-- Phase-to-Phase Brand-Level Pharmacoeconomics Spending
-- Departmental Monetary and Time Resource Allocations
-- Structures and Staffing
-- Departmental Funding Responsibilities
To view a summary of this report, visit
http://www.pharmacoeconomicsandhealthoutcomes.com/.
Contact Information: For more information or to learn about other Cutting Edge Information
research, contact:
David Richardson
+1-919-433-0216